TY - JOUR
T1 - Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin
T2 - The ASSENT-3 randomised trial in acute myocardial infarction
AU - The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators
AU - Van de Werf, F.
AU - Armstrong, P. W.
AU - Granger, C.
AU - Wallentin, L.
AU - Adgey, A. A.J.
AU - Aylward, P.
AU - Binbrek, A. S.
AU - Califf, R.
AU - Cassim, S.
AU - Diaz, R.
AU - Fanebust, R.
AU - Fioretti, P. M.
AU - Huber, K.
AU - Husted, S.
AU - Lindahl, B.
AU - López-Sendón, J. L.
AU - Mäkijärvi, M.
AU - Meyer, J.
AU - Navarro Robles, J.
AU - Pfisterer, M.
AU - Seabra-Gomes, R.
AU - Soares-Piegas, L.
AU - Sugrue, D.
AU - Tendera, M.
AU - Theroux, P.
AU - Toutouzas, P.
AU - Vahanian, A.
AU - Verheugt, F.
AU - Sarelin, H.
AU - Goetz, G.
AU - Bluhmki, E.
AU - Daclin, V.
AU - Danays, T.
AU - Houbracken, K.
AU - Kaye, J.
AU - Reilly, P.
AU - Hacke, W.
AU - von Kummer, R.
AU - Lesaffre, E.
AU - Bogaerts, K.
AU - Peeters, C.
AU - Fox, K. A.A.
AU - Brower, R.
AU - Hirsh, J.
AU - Maggioni, A.
AU - Tijssen, J.
AU - Weaver, D.
AU - Beernaert, A.
AU - Beysen, N.
AU - Broccard, A. F.
N1 - Funding Information:
We thank the study coordinators, nurses, and monitors in the participating countries and the patients who volunteered for the ASSENT 3 trial. The secretarial assistance of Anita Meuris in preparing the paper is greatly appreciated. The study was supported by Boehringer Ingelheim, Germany; Genentech, South San Francisco, CA, USA; and Aventis, Bridgewater, NJ, USA.
PY - 2001/8/25
Y1 - 2001/8/25
N2 - Background: Current fibrinolytic therapies fail to achieve optimum reperfusion in many patients. Low-molecular-weight heparins and platelet glycoprotein IIb/IIIa inhibitors have shown the potential to improve pharmacological reperfusion therapy. We did a randomised, open-label trial to compare the efficacy and safety of tenecteplase plus enoxaparin or abciximab, with that of tenecteplase plus weight-adjusted unfractionated heparin in patients with acute myocardial infarction. Methods: 6095 patients with acute myocardial infarction of less than 6 h were randomly assigned one of three regimens: full-dose tenecteplase and enoxaparin for a maximum of 7 days (enoxaparin group; n=2040), half-dose tenecteplase with weight-adjusted low-dose unfractionated heparin and a 12-h infusion of abciximab (abciximab group; n=2017), or full-dose tenecteplase with weight-adjusted unfractionated heparin for 48 h (unfractionated heparin group; n=2038). The primary endpoints were the composites of 30-day mortality, in-hospital reinfarction, or in-hospital refractory ischaemia (efficacy endpoint), and the above endpoint plus in-hospital intracranial haemorrhage or in-hospital major bleeding complications (efficacy plus safety endpoint). Analysis was by intention to treat. Findings: There were significantly fewer efficacy endpoints in the enoxaparin and abciximab groups than in the unfractionated heparin group: 233/2037 (11.4%) versus 315/2038 (15.4%; relative risk 0.74 [95% CI 0.63-0.87], p=0.0002) for enoxaparin, and 223/2017 (11.1%) versus 315/2038 (15.4%; 0.72 [0.61-0.84], p<0.0001) for abciximab. The same was true for the efficacy plus safety endpoint: 280/2037 (13.7%) versus 347/2036 (17.0%; 0.81 [0.70-0.93], p=0.0037) for enoxaparin, and 287/2016 (14.2%) versus 347/2036 (17.0%; 0.84 [0.72-0.96], p=0.01416) for abciximab. Interpretation: The tenecteplase plus enoxaparin or abciximab regimens studied here reduce the frequency of ischaemic complications of an acute myocardial infarction. In light of its ease of administration, tenecteplase plus enoxaparin seems to be an attractive alternative reperfusion regimen that warrants further study.
AB - Background: Current fibrinolytic therapies fail to achieve optimum reperfusion in many patients. Low-molecular-weight heparins and platelet glycoprotein IIb/IIIa inhibitors have shown the potential to improve pharmacological reperfusion therapy. We did a randomised, open-label trial to compare the efficacy and safety of tenecteplase plus enoxaparin or abciximab, with that of tenecteplase plus weight-adjusted unfractionated heparin in patients with acute myocardial infarction. Methods: 6095 patients with acute myocardial infarction of less than 6 h were randomly assigned one of three regimens: full-dose tenecteplase and enoxaparin for a maximum of 7 days (enoxaparin group; n=2040), half-dose tenecteplase with weight-adjusted low-dose unfractionated heparin and a 12-h infusion of abciximab (abciximab group; n=2017), or full-dose tenecteplase with weight-adjusted unfractionated heparin for 48 h (unfractionated heparin group; n=2038). The primary endpoints were the composites of 30-day mortality, in-hospital reinfarction, or in-hospital refractory ischaemia (efficacy endpoint), and the above endpoint plus in-hospital intracranial haemorrhage or in-hospital major bleeding complications (efficacy plus safety endpoint). Analysis was by intention to treat. Findings: There were significantly fewer efficacy endpoints in the enoxaparin and abciximab groups than in the unfractionated heparin group: 233/2037 (11.4%) versus 315/2038 (15.4%; relative risk 0.74 [95% CI 0.63-0.87], p=0.0002) for enoxaparin, and 223/2017 (11.1%) versus 315/2038 (15.4%; 0.72 [0.61-0.84], p<0.0001) for abciximab. The same was true for the efficacy plus safety endpoint: 280/2037 (13.7%) versus 347/2036 (17.0%; 0.81 [0.70-0.93], p=0.0037) for enoxaparin, and 287/2016 (14.2%) versus 347/2036 (17.0%; 0.84 [0.72-0.96], p=0.01416) for abciximab. Interpretation: The tenecteplase plus enoxaparin or abciximab regimens studied here reduce the frequency of ischaemic complications of an acute myocardial infarction. In light of its ease of administration, tenecteplase plus enoxaparin seems to be an attractive alternative reperfusion regimen that warrants further study.
UR - http://www.scopus.com/inward/record.url?scp=0035949117&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035949117&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(01)05775-0
DO - 10.1016/S0140-6736(01)05775-0
M3 - Article
C2 - 11530146
AN - SCOPUS:0035949117
SN - 0140-6736
VL - 358
SP - 605
EP - 613
JO - Lancet
JF - Lancet
IS - 9282
ER -
